Clinical Trials Browser

Phase 3 × zipalertinib × 90 days × Clear all

NCT05973773 2026-03-10

REZILIENT3

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Diseases

NCT07128199 2026-02-03

REZILIENT4

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms